🇺🇸 FDA
Patent

US 10314908

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

granted A61KA61K2039/55561A61K31/00

Quick answer

US patent 10314908 (Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation) held by The United States of America as represented by the Secretary of the Department of expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Department of
Grant date
Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/55561, A61K31/00, A61K31/365, A61K31/519